REMARKS

Applicants hereby claim priority to the applications listed below and request a filing receipt reflecting the same.

This application:

- ➤ is a divisional application of U.S.S.N. 09/503,219 filed February 2, 2000
- which claims benefit of U.S.S.N. 60/118,335 filed February 3, 1999.

The specification has been amended to reflect this priority claim as well as the current status of the priority applications. In addition, the specification has been amended to incorporate these applications by reference.

The specification has also been amended to comply with 37 C.F.R. § 1.821-1.825. A paper copy of the "Sequence Listing" which is believed to comply with 37 C.F.R. § 1.821-1.825 is submitted to replace the current "Sequence Listing." In addition, a computer readable form of the "Sequence Listing" is submitted along with a Statement declaring that the information recorded on the diskette is identical to the paper copy.

Applicants elect to prosecute Group II (Claims 1-17 [1-7]) as set forth in Paper No. 6 of the parent application without traverse. These claims are directed to a method of modulating migration of a cell within, or to the skin of a mammal, comprising administering to the said mammal an effective amount of an <u>antagonist of CCR6</u>. Claims 8-20 have been withdrawn as they are drawn to non-elected inventions. For greater clarity, Claims 1-7 have been cancelled and the subject matter that is directed to the presently claimed invention has been incorporated into new claims 21-42. Support for these new claims can be found in the specification and the originally filed claims (e.g., on page 3, lines 21-31 and in Claims 1-7). No new matter has been added by these claim amendments.

CONCLUSION

It is believed that the foregoing amendments place this application now in condition for allowance. Early and favorable action allowing pending claims 21-42 is respectfully solicited.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION Patent Department, K-6-1, 1990 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530 Sandy Xaradic, Ph.D. Reg. No. 45,997 Patent Agent (908) 298-7221